Aplastic Anemia News and Research RSS Feed - Aplastic Anemia News and Research

Study of genetic mutations could lead to optimized treatment plans for aplastic anemia patients

Study of genetic mutations could lead to optimized treatment plans for aplastic anemia patients

Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study, appearing in the New England Journal of Medicine, could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient. [More]
Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Induced pluripotent stem cells (iPSCs) -- adult cells reprogrammed back to an embryonic stem cell-like state--may better model the genetic contributions to each patient's particular disease. In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer. [More]
Longer donor leukocyte telomere length linked to improved survival following HCT

Longer donor leukocyte telomere length linked to improved survival following HCT

Among patients with severe aplastic anemia who received stem cell transplant from an unrelated donor, longer leukocyte (white blood cells) telomere length (a structure at the end of a chromosome) was associated with increased overall survival at 5 years, according to a study in the February 10 issue of JAMA. [More]
SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

The Fred Hutchinson Cancer Research Center Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized for outperforming its anticipated one-year survival rate for allogeneic transplant patients. [More]
Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets. [More]
Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S. [More]
Scientists identify gene mutation that causes aplastic anemia

Scientists identify gene mutation that causes aplastic anemia

An international team of scientists has identified a gene mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells. [More]
Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates. [More]
UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. [More]
Eleanor Roosevelt's cause of death and end of life issues examined during clinicopathological conference

Eleanor Roosevelt's cause of death and end of life issues examined during clinicopathological conference

Today, the Medical Alumni Association of the University of Maryland School of Medicine (SOM) along with notable national experts review the cause and end of life issues surrounding the death of one of the most prominent figures of the 20th Century: former First Lady and leading women's and civil rights advocate Eleanor Roosevelt as part of the 21st Annual Historical Clinicopathological Conference. [More]
CIBMTR recognizes SCCA's Fred Hutchinson Bone Marrow Transplant Program

CIBMTR recognizes SCCA's Fred Hutchinson Bone Marrow Transplant Program

The Fred Hutchinson Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized by the Center for International Blood and Marrow Transplant Research for outperforming its expected one-year survival rate for allogeneic transplant patients. The results published by the CIBMTR, analyzed the National Marrow Donor Program's (NMDP) registry of 168 U.S. transplant centers over a three-year period for its 2013 Transplant Center-Specific Survival Report. [More]
Researchers discover pre-leukemic stem cell that triggers relapse in patients with AML

Researchers discover pre-leukemic stem cell that triggers relapse in patients with AML

Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML). [More]
Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates. [More]
FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy. [More]
Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body. [More]
Advertisement
Advertisement